Octreotide in the treatment of bleeding due to angiodysplasia of the small intestine.
Three patients with a history of bleeding due to small bowel angiodysplasia (repeated melena or occult fecal blood with serious anemia) were treated for 10-40 months with octreotide, a somatostatin analog that reduces the splanchnic flow. A dose of 0.1 mg subcutaneously twice a day was followed by an increase in hemoglobin, and reduction or elimination of the need for transfusions. There were no further melena episodes, and stool hemoglobin became stably negative in two cases. Suspension of the drug after 6 months in one case was followed by renewed bleeding, and resumption led to a further response. Lower doses tried in another case were ineffective. Although these uncontrolled clinical cases do not prove its efficacy, octreotide appears to be beneficial in the control and prevention of bleeding due to diffuse small bowel angiodysplasia. There is no evidence that it results in regression of angiodysplasias, as they persisted in the patient subjected to control jejunoileoscopy.
Rossini
F P
FP
Department of Gastroenterology and Gastrointestinal Endoscopy, S. Giovanni A. S. Hospital, Turin, Italy.
Arrigoni
A
A
Pennazio
M
M
D000293:Adolescent; D000368:Aged; D016888:Angiodysplasia / Q000150:complications*; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007410:Intestinal Diseases / Q000150:complications*; D007421:Intestine, Small; D008875:Middle Aged; D015282:Octreotide / Q000009:adverse effects / Q000627:therapeutic use*
D015282:Octreotide